Ranbaxy Pharmaceuticals Canada Inc., a subsidiary of Ranabxy Laboratories,  has recalled one batch of RAN-gabapentin, a medication used to treat epilepsy, (RAN-gabapentin capsules 100 mg, batch no 2582026, expiry date December 2015) from Canadian market due to cross-contamination during the manufacturing process with Etodolac, a non-steroidal anti-inflammatory drug.

The population at risk includes those who are hypersensitive to Etodolac, acetylsalicylic acid (ASA) or any other non-steroidal anti-inflammatory drug. The risks include mild skin rashes, hives, and in rare instances, anaphylactoid reactions have also been reported during drug therapy with Etodolac.

For most adult patients, exposure to trace amounts of Etodolac will not represent a health risk and there are no contraindications for taking the two medications together.